Aurora kinase B is an independent protective factor in superficial bladder tumours with a dysfunctional G1 checkpoint

BJU International

Volumn 102, Issue 2, 2008, Pages 247-252

  Bruyere, Franck ^a   Corcoran, Niall M ^a   Berdjis, Navid ^a   Namdarian, Benjamin ^a   Pedersen, John ^b   Ockrim, Jeremy ^a   Voelzke, Bryan B ^a   Costello, Anthony J ^a   Hovens, Christopher M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Tissupath Pty Ltd   (Australia)

Author keywords

Aurora kinase; Carcinoma; Immunohistochemistry; Recurrence; Transitional cell

Indexed keywords

AURORA A KINASE; AURORA B KINASE; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER CLASSIFICATION; CANCER GRADING; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SUPERFICIAL CANCER; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; G1 PHASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS;

EID: 45449083105     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07572.x     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2006 56 : 106 30
2. Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995 153 : 1823 6
3. Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer: progression and recurrence. J Urol 1983 130 : 1083 6
4. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005 5 : 773 85
5. Tseng TC, Chen SH, Hsu YP, Tang TK. Protein kinase profile of sperm and eggs: cloning and characterization of two novel testis-specific protein kinases (AIE1, AIE2) related to yeast and fly chromosome segregation regulators. DNA Cell Biol 1998 17 : 823 33
6. Ota T, Suto S, Katayama H et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002 62 : 5168 77
7. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003 3 : 51 62
8. Li D, Zhu J, Firozi PF et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003 9 : 991 7
9. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004 10 : 2065 71
10. Wang X, Zhou YX, Qiao W et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 2006 25 : 7148 58
11. Yamamoto Y, Matsuyama H, Kawauchi S et al. Biological characteristics in bladder cancer depend on the type of genetic instability. Clin Cancer Res 2006 12 : 2752 8
12. Mhawech-Fauceglia P, Fischer G, Beck A, Cheney RT, Herrmann FR. Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol 2006 32 : 439 44
13. Sen S, Zhou H, Zhang RD et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002 94 : 1320 9
14. Smith SC, Oxford G, Baras AS et al. Expression of ral GTPases, their effectors, and activators in human bladder cancer. Clin Cancer Res 2007 13 : 3803 13
15. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004 4 : 927 36
16. Haupt S, Haupt Y. Importance of p53 for cancer onset and therapy. Anticancer Drugs 2006 17 : 725 32
17. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994 331 : 1259 64
18. Mitra AP, Datar RH, Cote RJ. Molecular staging of bladder cancer. BJU Int 2005 96 : 7 12
19. Schmitz-Drager BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000 38 : 691 9
20. Bartek J, Lukas J. DNA repair: damage alert. Nature 2003 421 : 486 8
21. Tonini T, Hillson C, Claudio PP. Interview with the retinoblastoma family members: do they help each other? J Cell Physiol 2002 192 : 138 50
22. Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 1995 71 : 831 5
23. Cote RJ, Dunn MD, Chatterjee SJ et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998 58 : 1090 4
24. Lynch CF, Cohen MB. Urinary system. Cancer 1995 75 : 316 29
25. Andrews PD. Aurora kinases: shining lights on the therapeutic horizon? Oncogene 2005 24 : 5005 15
26. Comperat E, Camparo P, Haus R et al. Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms. Virchows Arch 2007 450 : 419 24
27. Vader G, Medema RH, Lens SM. The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol 2006 173 : 833 7